WASHINGTON (AP) ‚ Federal regulators are reviewing data that suggest the asthma medication Xolair can cause heart attacks, strokes and other potentially deadly problems.
The Food and Drug Administration says preliminary results from a study of 5,000 patients taking the drug suggests an increased risk of heart problems and stroke. The drug's manufacturer Genentech, a unit of Swiss pharmaceutical giant Roche, designed the study to track the long-term safety of the drug over five years.
A representative for Genentech says final results are not expected until 2012. The South San Francisco-based company says it will continue gathering safety information about Xolair.
The FDA says patients should continue taking the drug as directed.
Copyright 2009 The Associated Press.
|< Prev||Next >|